GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Operating Margin %

Innovent Biologics (HKSE:01801) Operating Margin %

: -16.35% (As of Jun. 2023)
View and export this data going back to 2018. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Innovent Biologics's Operating Income for the six months ended in Jun. 2023 was HK$-483 Mil. Innovent Biologics's Revenue for the six months ended in Jun. 2023 was HK$2,955 Mil. Therefore, Innovent Biologics's Operating Margin % for the quarter that ended in Jun. 2023 was -16.35%.

Good Sign:

Innovent Biologics Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Innovent Biologics's Operating Margin % or its related term are showing as below:

HKSE:01801' s Operating Margin % Range Over the Past 10 Years
Min: -16383.15   Med: -89.36   Max: -1.1
Current: -16.25


HKSE:01801's Operating Margin % is ranked better than
69.66% of 1025 companies
in the Biotechnology industry
Industry Median: -179.29 vs HKSE:01801: -16.25

Innovent Biologics's 5-Year Average Operating Margin % Growth Rate was 70.60% per year.

Innovent Biologics's Operating Income for the six months ended in Jun. 2023 was HK$-483 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1,103 Mil.

Warning Sign:

Innovent Biologics Inc has never been profitable in the past 3 years. It lost money every year.


Innovent Biologics Operating Margin % Historical Data

The historical data trend for Innovent Biologics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only -122.05 -1.10 -45.42 -56.67 -16.25

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.74 -54.12 -59.13 -16.35 -16.18

Competitive Comparison

For the Biotechnology subindustry, Innovent Biologics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Operating Margin % falls into.



Innovent Biologics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Innovent Biologics's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-2883.229 / 5088.177
=-56.67 %

Innovent Biologics's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-483.125 / 2954.883
=-16.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (HKSE:01801) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Innovent Biologics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines